OnKure Therapeutics reported Q1 2026 results highlighting the nomination of two next-generation PI3Kα pan-mutant selective inhibitors, OKI-355 for vascular anomalies and OKI-345 for breast cancer. The company secured $150 million in private placement funding to support clinical development planned for 2027, with $192 million cash on hand expected to fund operations through 2029. OnKure is focusing on these inhibitors to provide targeted therapies with fewer toxicities and plans to submit IND applications to the FDA in the first half of 2027. The company also announced it will not independently pursue further development of OKI-219, another PI3Kα inhibitor, shifting focus to the new candidates.
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
Rogers Communications has agreed to buy the remaining 25% stake in Maple Leaf Sports & Entertainment (MLSE) from Kilmer Sports for C$4.35 billion, making Rogers the sole owner. This move aims to strengthen Rogers' position in Canadian sports and ente...
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
